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Lysophosphatidic acid (LPA) is a bioactive phospholipid that
affects various biological functions, such as cell proliferation,
migration, and survival, through LPA receptors. Among them,
themotility of cancer cells is an especially important activity for
invasion and metastasis. Recently, AMP-activated protein
kinase (AMPK), an energy-sensing kinase, was shown to regu-
late cell migration. However, the specific role of AMPK in can-
cer cell migration is unknown. The present study investigated
whether LPA could induce AMPK activation and whether this
process was associated with cell migration in ovarian cancer
cells. We found that LPA led to a striking increase in AMPK
phosphorylation in pathways involving the phospholipase
C-3 (PLC-3) and calcium/calmodulin-dependent protein
kinase kinase  (CaMKK) in SKOV3 ovarian cancer cells.
siRNA-mediated knockdown of AMPK1, PLC-3, or
(CaMKK) impaired the stimulatory effects of LPA on cell
migration. Furthermore, we found that knockdownofAMPK1
abrogated LPA-induced activation of the small GTPase RhoA
and ezrin/radixin/moesin proteins regulating membrane dy-
namics as membrane-cytoskeleton linkers. In ovarian cancer
xenograft models, knockdown of AMPK significantly decreased
peritoneal dissemination and lung metastasis. Taken together,
our results suggest that activation of AMPK by LPA induces cell
migration through the signaling pathway to cytoskeletal dynam-
ics and increases tumor metastasis in ovarian cancer.
Lysophosphatidic acid (LPA)2 has been shown to participate
in diverse biological actions, including changes in cell shape,
motility, and proliferation, in a variety of cell types (1). Previous
studies have shown that LPAhas a role in early signaling events,
such as Ca2 mobilization, changes in cAMP accumulation,
and the activation of several protein kinases (1–4). Among
these pathological processes, the role of LPA in ovarian cancer
has been most extensively studied. LPA contributes to the
development, progression, and metastasis of ovarian cancer,
and its concentration is increased up to 80 M (in comparison
to the basal 1–5 M concentration) in both plasma and ascites
of ovarian cancer patients (5). In vitro studies have shown that
production of LPA levels was constitutively increased in ovar-
ian cancer cells but not in normal ovarian epithelial cells (6, 7).
Moreover, in a study of the expression of LPA receptor mRNA
and protein levels in ovarian cancer tissues, LPA2 and LPA3
were aberrantly up-regulated, but LPA1 was not changed (8, 9).
Overexpression of LPA2 and LPA3 are closely associated with
tumor progression in ovarian cancer cells (10–13). As evidence
of intracellular signaling in cancer cell migration, LPA induces
activation of Ras-MEKK1 (14), Rac1 (15), Ca2-dependent
Pyk2 (16), and the Rho/ROCK pathway (17), which indicates
that dynamic cytoskeletal rearrangement in LPA-mediated cell
migration is regulated through the coordination of complex
contexts (such as small GTPases, focal adhesion, and Ca2-de-
pendent signaling). However, the exact regulatory factors of
these molecular mechanisms underlying LPA-induced cell
migration have not been fully elucidated.
AMP-activated protein kinase (AMPK) is a highly conserved
sensor of cellular energy status in eukaryotes and is widely
known as a regulator of cell metabolism (18). It consists of a
heterotrimeric complex of a catalytic  subunit and regulatory
/ subunits (19, 20). AMPK is activated in response to an
increase in the ratio of AMP-to-ATP within the cell, and it is
phosphorylated at Thr-172 within the activation domain of the
 subunit by upstream kinases, LKB1 (21–23) and calmodulin-
dependent protein kinase kinase  (CaMKK) (24–26). Recent
studies introduced AMPK as an important regulatory factor in
cell migration (27–31). Activation of AMPK facilitates micro-
tubule dynamics (27) and tube formation (28) through the
increasing phosphorylation of cytoplasmic linker protein-170
and triggering the endothelial nitric oxide synthase pathway.
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Specifically, in cancer cells, AMPK increases cell migration
through the transcriptional up-regulation of integrins (29, 30)
and down-regulation of microRNA-451 levels (31). Therefore,
it is possible that AMPK promotes LPA-induced cell migration
by regulating dynamic cytoskeletal rearrangement in cancer
cells.
In this study, we investigated the role of AMPK in LPA-in-
duced cellmigration in ovarian cancer cells.We found that LPA
activates AMPK through Ca2-dependent signaling, including
PLC-3 and CaMKK. The activation of AMPK is essential for
LPA-induced cell migration by modulating the activation of
ezrin/radixin/moesin (ERM) proteins, which are involved in
actin filament/plasma membrane interactions, through the
Rho pathway. Therefore, these findings provided new insight
into the molecular mechanism of AMPK activation in cell
migration and indicated that AMPK may be a potential thera-
peutic target in ovarian cancer.
EXPERIMENTAL PROCEDURES
Materials—Lysophosphatidic acid (1-oleoyl-2-hydroxy-sn-
glycerol-3-phosphate) was purchased from Avanti Lipid (Ala-
baster, AL). Anti-phospho-acetyl-CoA carboxylase (ACC)
(Ser-79), anti-phospho-AMPK (Thr-172), anti-phospho-ERM,
anti-AMPK1, anti-ACC, and anti-ERM antibodies were pur-
chased from Cell Signaling Technology (New England Biolabs,
Beverly, MA). Anti-PLC-3, anti-Rac1, and anti-RhoA anti-
bodies were obtained from Santa Cruz Biotechnology, Inc.
(Santa Cruz, CA), and a -actin antibody and rhodamine-con-
jugated phalloidin were purchased from Sigma-Aldrich (St.
Louis, MO). Horseradish peroxidase-conjugated secondary
antibodies were obtained from the Kirkegaard and Perry Labo-
ratory (Gaithersburg, MD). Compound C, U73122, STO-609,
pertussis toxin, PD98059, and Y27632 were obtained from
Calbiochem.
Cell Culture—Human ovarian cancer SKOV3 and OVCAR3
cell lines were purchased from theAmericanTypeCulture Col-
lection. Human ovarian surface epithelial cell line HIO-80
(immortalized by SV40 large T) was obtained fromDr. Andrew
K. Godwin (Fox Chase Cancer Center, Philadelphia, PA).
SKOV3 cells were cultured in RPMI 1640 medium with 10%
FBS, 100 units/ml of penicillin, and 100g/ml of streptomycin.
OVCAR3 cells were cultured in DMEM containing 10% FBS
and antibiotics. HIO-80 cells were cultured in a 1:1 mixture of
medium199 (Earle’s salts, L-glutamine, 2.2 g/liter sodiumbicar-
bonate, 25 mM HEPES) and MCDB-105 (L-glutamine, 25 mM
HEPES) with 4% FBS, 0.2 units/ml pork insulin, and antibiotics.
All cells were grown at 37 °C in a humidified 5%CO2 incubator.
Immunoblot Analysis—Cells were serum-starved overnight
prior to treatment with the indicated agents. Whole cell lysates
were prepared in lysis buffer, as described previously (32).
Lysates were then centrifuged at 14,000 g for 10 min at 4 °C.
Supernatants were electrophoresed on SDS-PAGE (8%) gels
and transferred to nitrocellulosemembranes.Membranes were
incubated overnight at 4 °C with primary antibodies and then
washed three times inTris-buffered saline/0.1%Tween 20 prior
to 1 h incubation with horseradish peroxidase-conjugated sec-
ondary antibodies at room temperature. Proteins were then
detected via ECL reagents (Amersham Biosciences).
Small Interfering RNA Transfection—siRNA duplexes di-
rected against LPA2 (nucleotides 867–885), PLC-3 (nucleo-
tides 483–501), AMPK1, and CaMKK were synthesized or
purchased from Dharmacon, Inc. (Lafayette, CO). The presyn-
thesized control siRNA duplexes (luciferase GL3 duplex) were
also purchased and used as control oligonucleotides. The cells
were transfected with 20 nM siRNA using Lipofectamine (Invit-
rogen) in serum-free conditions. After 4 h of transfection, the
cells were washed and supplemented with fresh medium con-
taining 10% FBS. The cells were incubated for 48 h prior to use.
Transwell Migration Analysis—Chemotactic directional
migration was evaluated using a modified Boyden chamber
(Neuroprobe, Inc., Gaithersburg, MD). Porous filters (8 M)
were coated by passive adsorption of type I collagen (Sigma) by
incubationwith 20g/ml collagen in 0.1M acetic acid overnight
at 4 °C. Cells (2  104) were plated in the upper chamber in
medium containing 1MLPAwith orwithout agents (pertussis
toxin, U73122, STO-609, compound C, PD98059, or Y27632)
as indicated and allowed tomigrate for 4 h. Non-migrating cells
were removed from the upper chamber with a cotton swab,
whereas migrating cells adherent to the underside of the filter
were fixed with 4% paraformaldehyde, permeated with 0.2%
Triton X-100, and stained with Hoechst 33342 solution. The
migrated cells were photographed and quantified by fluores-
cent microscopy at a magnification of 100 by counting the
stained cells from three randomly chosen high power fields.
The mean values obtained from vehicle-treated cells were
expressed as 1.0, and others were relative values. Each value is
expressed as the mean  S.D. of three independent experi-
ments performed in triplicate.
Wound Healing Analysis—Control or AMPK1 siRNA-
transfected SKOV3 or OVCAR3 cells (2 105) were seeded on
a type I collagen-coated 35-mm dish and incubated for 24 h
until a confluent monolayer was formed. Cells were incubated
overnight in RPMI 1640 supplemented with 0.1% (w/v) BSA.
The cell monolayer was then scratched with a pipette tip.
Subsequently, cells were washed twice with PBS, and the
migration of cells into the wound area was induced by treat-
ment of 1 M LPA. For kinetic analysis, two individual fields
of the wound area on a 35-mm dish were photographed at
12 h post-wounding.
Thymidine Incorporation Assay—The assay was performed
as described previously (33) with some modifications. Control
or LPA2 siRNA-transfected SKOV3 cells were seeded into six-
well plates at 2 105 cells/well for 24 h. Upon serum depriva-
tion for 24 h to reach quiescence, the cells were treated with
LPA. After 18 h incubation, cells were pulse-labeled with
[3H]thymidine (0.8 Ci/ml) for 6 h. The pulse-labeled cells
were followed by three quick washes with PBS to remove the
remaining unincorporated labels and then fixed with ice-cold
10% trichloroacetic acid for 15 min at 4 °C. The fixed cells were
then lysed with 0.4 NNaOHwith 1% SDS, and the radioactivity
was counted by a scintillation counter.
Rho GTPase Activation Assay—The activation of RhoA or
Rac1 was measured using the GST-Rho binding domain of
Rhotekin or GST-Rac binding domain of Pak bound to gluta-
thione-Sepharose beads. Cells were lysed in lysis buffer (50 mM
Tris (pH 7.5), 10mMMgCl2, 0.5 MNaC1, and 1%TritonX-100),
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and the lysates were incubated with GST-Rho binding domain
of Rhotekin orGST-Rac binding domain of Pak beads at 4 °C for
40min. The beads were collected by centrifugation andwashed
three timeswithwashing buffer (25mMTrisHCl (pH7.6), 1mM
DTT, 30 mM MgCl2, 40 mM NaCl, and 1% (v/v) Nonidet P-40).
Proteins were eluted from beads by boiling in 2 sample buffer
for 5 min. The precipitates were analyzed with antibodies spe-
cific for RhoA or Rac1. To equalize the cellular proteins in each
sample, total cell lysates were also run on gels and subjected to
Western blot analysis.
RT-PCR and Real-time Quantitative RT-PCR—cDNA (1g)
was reverse-transcribed from 3 g of total cellular RNA pre-
pared using TRIzol reagent (Invitrogen) according to the man-
ufacturer’s method, using oligo(dT) primers andmurine leuke-
mia virus reverse transcriptase (Promega, Madison, WI).
Amplification parameters were as follows: 30 s at 94 °C for
denaturation, 30 s at 58 °C for primer annealing, and 30 s at
72 °C for polymerization. PCRs were performed for 35 cycles.
The same amount of cDNA was amplified for 25 cycles using
the following specific GAPDH primers. Primer sequences were
as follows: LPA1, 5-ATGGCTGGGAGTTGATTGAG-3 and
5-GAAGTTGGTGTCCCGTGTCT-3; LPA2, 5-TTGTCTT-
CCTGCTCATGGTG-3 and 5-CTCGGCAAGAGTACACA-





For real-time quantitative RT-PCR, total RNA (100 ng) was
amplified with a One Step SYBR RT-PCR kit using a Light-
Cycler 2.0 PCR system (Roche). PCR conditions consisted of a
10-min hot start at 95 °C, followed by 45 cycles of 15 s at 95 °C,
10 s at 60 °C, and 30 s at 72 °C. Expression levels of eachmRNA
were compared after normalization against the expression of
GAPDH. This experiment was repeated three times.
Immunofluorescence Assay—Control or AMPK1 knock-
down cells were cultured overnight on 20 g/ml collagen
I-coated coverslips and then treated with 1 M LPA for 5 min.
The cells were washed twice with PBS and fixed with 4% para-
formaldehyde for 10 min at room temperature. The coverslips
were washed twice with PBS and blocked with BSA (5%) in
tris-buffered saline with tween-20 and permeabilized with PBS
containing 1%horse serum and 0.2%TritonX-100 for 30min at
room temperature. To visualize F-actin, the cells were incu-
bated with rhodamine-conjugated phalloidin for 1 h at room
temperature andwashed four timeswith PBS. To visualize focal
adhesions, permeabilized cells were incubated with p-ERM
antibody (1/100) diluted in PBS containing 1% horse serum
overnight at 4 °C. The cells were then washed four times with
PBS and incubated with FITC-conjugated anti-rabbit second-
ary antibody (1/500) for 1 h at room temperature. After being
washed four times with PBS, cells were then analyzed with a
laser-scanning confocalmicroscope imaging system (Olympus,
FV 1000).
Lentivirus Transduction and Stable Cell Line Generation—
293T cells were transfected with plasmids encoding control or
AMPK1 shRNA (sequence: CCGGCCTGGAAGTCACACA-
ATAGAACTCGAGTTCTATTGTGTGACTTCCAGGTT-
TTT) in pLKO vectors (Sigma-Aldrich), vesicular stomatitis
virusG and 8.9 for 16 h, afterwhich themediumwas replaced.
Following 48-h culture,media containing lentiviruseswere har-
vested and used for transduction of target cells for 24 h. Stable
cell lines were selected in the presence of 3 g/ml puromycin
(Sigma-Aldrich) and then used for xenograft models.
Animals and Xenograft Models—All mice were bred and
maintained in specific pathogen-free conditions at the animal
facility of the Seoul National University College of Medicine.
All animal experiments were performed with the approval of
the institutional animal care and use committee of Seoul
National University.
To assess tumor metastasis of the cancer cells, control
knockdown SKOV3 (SKOV3shControl) or AMPK1 knockdown
SKOV3 cells (SKOV3shAMPK1, 3  105) were injected intra-
peritoneally into 8-week-old NOD/scid/IL-2R/(NOG)
mice (The Jackson Laboratory, Bar Harbor, ME). Eight weeks
after the injection, the mice were euthanized, and primary
tumor masses in the peritoneum for ovarian cancer, liver, and
lung were fixed in 4% paraformaldehyde for 24 h. Sections (4
m) were stained with hematoxylin and eosin. The number of
tumormasses in the liver and lungwas counted under a dissect-
ing microscope.
Statistical Analysis—Student’s t test was used to compare
data between two groups. Values are expressed asmeans S.D.
of at least triplicate samples. p  0.05 was considered statisti-
cally significant.
RESULTS
LPA Induces Activation of AMPK in Ovarian Cancer Cells—
Several studies have recently reported that elevated activation
of AMPK occurs in human cancer tissues (34), and the molec-
ular mechanisms linking agonist-mediated AMPK regulation
are important for cell motility (28–30). Thus, we sought to
characterize the phosphorylation of AMPK by LPA known as
the chemotatic factor (1) in SKOV3 ovarian cancer cell lines.
The phosphorylation of AMPK was gradually increased and
peaked at 2 min after LPA treatment. After 20 min it had
returned to basal levels. Consistent with the increase in AMPK
activation, the phosphorylation of its substrate, ACC, was also
increased in SKOV3 cells (Fig. 1A). Next, we examinedwhether
this phosphorylation of AMPK was cancer-specific. Three dif-
ferent cell lines (SKOV3, OVCAR3, and HIO-80) were pre-
pared, and different doses of LPA (0–10M) were applied for 2
min. Both ovarian cancer cell lines, SKOV3 and OVCAR3,
showed gradually increased phosphorylation of AMPK and
ACC (Fig. 1B). However, HIO-80, a non-cancer ovarian surface
epithelial cell line, was not affected by LPA (Fig. 1B). These data
showed that LPA increases the phosphorylation of AMPK and
its substrate, ACC, in both SKOV3 and OVCAR3 cells.
LPA Induces Activation of AMPK through the LPA2 in Ovar-
ian Cancer Cells—Different responses to LPA for normal and
cancer cells might be caused by differential expression of LPA
receptors (8, 9). Thus, we sought to confirmmRNA expression
of LPA receptor subtypes using quantitative real-time PCR.
LPA2 and LPA3, but not LPA1, are aberrantly up-regulated in
ovarian cancer cells (Fig. 1C). To identify which LPA receptor
subtypes is involved in phosphorylation of AMPK, we explored
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the activation of AMPK in LPA2 or LPA3 knockdown cells. The
phosphorylation of AMPK in response to LPAwas significantly
attenuated by knockdown of LPA2 but not by knockdown of
LPA3 (Fig. 1D). Furthermore, to verify the role of LPA2, we
assessed the effects of LPA2 knockdown on LPA-induced cell
migration and proliferation. Interestingly, the knockdown of
LPA2 suppressed LPA-induced cell migration but not cell pro-
liferation (Fig. 1, E and F). These results indicated that phos-
phorylation of AMPK by LPA is associated with LPA2 activa-
tion in ovarian cancer cell migration.
Activation of AMPK Is Required for LPA-induced Cell
Migration—Considering the result in Fig. 1, activation of
AMPK by LPA might be involved in changes of ovarian cancer
cell motility. To define the specific relevance in LPA-induced
cell migration, the chemotactic migration assay after transfec-
tion with control or AMPK1 siRNA was accomplished in
SKOV3 cells. AMPK1 siRNA-transfected cells significantly
attenuated LPA-induced cell migration compared with control
siRNA-transfected cells (Fig. 2A) and suppressed LPA-induced
phosphorylation of AMPK and ACC (B). In addition, a wound
FIGURE 1. LPAactivatesAMPK throughLPA2 inovarian cancer cells.A, SKOV3 cellswere treatedwith 1MLPAunder serum-free conditions, and cell lysates
wereprepared at different times as indicated.B, SKOV3,OVCAR3, andHIO-80 cellswere treatedwith LPA for 2minunder serum-free conditions, and cell lysates
were prepared at the indicated concentrations. The phosphorylation of AMPK and ACCwas analyzed by immunoblot analysis. AMPK1 and ACCwere used as
experimental controls, and -actin was used as the loading control. These results represent one of three independent experiments. C, the expression levels of
LPA1, LPA2, LPA3, and GAPDH were analyzed by quantitative real-time PCR. The obtained results were quantified and normalized relative to GAPDH levels.
D, SKOV3 cells were transfected with control, LPA2, or LPA3 siRNA for 48 h. Cell lysates were prepared after 1 M LPA treatment for 2 min under serum-free
conditions and then subjected to immunoblot analysis using specific antibodies against p-AMPK, AMPK1, and -actin. The efficiency of siRNA interfer-
ence against LPA2 or LPA3 was tested by RT-PCR. SKOV3 cells were transfected with control or LPA2 siRNA for 48 h. E, control or LPA2 siRNA-transfected cells
were examined for the migration activity after the treatment with 1 M LPA for 4 h. The number of migrated cells was determined by counting them in three
randomly chosen high power fields. Each value is expressed as the mean S.D. of three independent experiments, each performed in triplicate. *, p 0.05
comparedwith LPA alone. F, for the study of cell proliferation activity induced by LPA2, LPA2 siRNA-transfected cells were incubated in 10M LPA for 18 h and
then pulse-labeled with [3H]thymidine, and the amount of [3H]thymidine incorporation was measured by scintillation counting.
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healing assaywas used to assess the potential effects of constant
doses of LPA on cell migration in vitro. When a confluent
monolayer was scratched, the migration of AMPK1
siRNA-transfected cells into the wounded area was signifi-
cantly reduced in the presence of LPA compared with control
siRNA-transfected cells. We also confirmed that the LPA-in-
duced cell migration was reduced by knockdown of AMPK1
in OVCAR3 cells, another ovarian cancer cell line, using the
wound healing assay (Fig. 2C). These data demonstrated that
AMPK acts as a key regulator in LPA-induced cell migration.
LPA Induces Activation of AMPK through Ca2-dependent
Signaling in Cell Migration—It has been reported that LPA
increases the intracellular calcium concentration in ovarian
cancer cells (35) and induces cell migration through Ca2-de-
pendent Pyk2 activation (16). Additionally, activation of AMPK
is triggered by an increase in the intracellular calcium concen-
tration without detectable changes in the AMP-to-ATP ratio
(24). Thus, we wished to characterize a possible Ca2-depen-
dent signaling pathway responsible for the LPA-induced phos-
phorylation of AMPK. SKOV3 cells that were incubated with
theGi/o inhibitor pertussis toxin, a PLC inhibitor (U73122), or a
specific CaMKK inhibitor (STO-609) were suppressed in the
LPA-stimulated phosphorylation of AMPK. This effect was not
observedwith a selectiveMEK inhibitor (PD98059) (Fig. 3A). In
addition, these inhibitors significantly reduced LPA-induced
cell migration (Fig. 3B). Consistent with our results, previous
report revealed that PD98059 did not affect LPA-induced cell
migration in ovarian cancer cells (17). We have shown previ-
ously that a ternary complex consisting of the LPA2 receptor
NHERF2 and PLC-3 may play a key role in the LPA-mediated
Ca2 signaling pathway (36). Therefore, AMPKmight be regu-
lated by intracellular Ca2 induced through PLC-3 activation.
To understand the role of PLC-3 in the LPA-induced activa-
tion of AMPK, we explored the activation of AMPK and cell
migration in PLC-3 knockdown cells upon LPA treatment.
Knockdown of PLC-3 abolished the activation of AMPK and
cell migration upon LPA treatment (Fig. 3, C and D). In addi-
tion, knockdown of CaMKK, an upstream AMPK kinase in
Ca2 signaling, severely impaired the LPA-induced activation
of AMPK and cell migration (Fig. 3, E and F). These results
suggested that Ca2-dependent signaling, including PLC-3
andCaMKK, is the upstreampathway of LPA-inducedAMPK
phosphorylation and increases LPA-induced cell migration
through the activation of AMPK.
LPA Activates RhoA through AMPK Activation—Cell migra-
tion begins with an initial protrusion or extension of the plasma
membrane via cytoskeletal rearrangement. The cytoskeleton is
regulated by activation of Rho-GTPases (37). LPA activates
RhoA through Rho-specific guanine nucleotide exchange fac-
tors that promote RhoA-GTP accumulation (38). Therefore, it
is likely that RhoA or Rac1 may serve as a downstream effector
of AMPK to facilitate LPA-induced cell migration through
FIGURE 2. LPA-activated AMPK induces cell migration in ovarian cancer cells. SKOV3 cells were transfected with control or AMPK1 siRNA for 48 h. A, the
cells were used for a transwell migration assay after treatment with 1M LPA for 4 h as described under “Experimental Procedures.” Each value is expressed as
the mean S.D. of three independent experiments, each performed in triplicate. *, p 0.05 compared with LPA alone. B, the cell lysates were prepared after
1 M LPA treatment for 2 min under serum-free conditions and then subjected to immunoblot analysis using specific antibodies against p-AMPK, p-ACC,
AMPK1, ACC, and-actin. These results represent oneof three independent experiments.C, SKOV3orOVCAR3 cellswere transfectedwith control or AMPK1
siRNA for 48h. The cellswereplatedona collagen type I-coated35-mmdish and incubateduntil a confluentmonolayerwas formed. After being serum-starved
overnight in RPMI 1640 or DMEM containing 0.1% BSA, a cell-free spacewas created by scraping through themonolayer. Migrationwas induced by treatment
with 1 M LPA for 12 h. Magnifications, 200.
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actin rearrangement. To assess this possibility, we first exam-
ined the effect of LPA on RhoA and Rac1 activation in SKOV3
cells. Consistent with the activation of AMPK, LPA activated
RhoA and Rac1 as early as 30 s and peaked at 2 min (Fig. 4A).
Moreover, knockdown of AMPK1 by siRNA transfection sig-
nificantly attenuated LPA-induced RhoA activation, but not
Rac1 activation (Fig. 4B). Therefore, these results demonstrated
that AMPK plays an important role in LPA-induced RhoA acti-
vation for actin rearrangement.
AMPK Activates ERM Proteins through RhoA Activation in
LPA-induced Cell Migration—The ERM proteins, concen-
trated in actin-rich cell surface structures, cross-link the actin
cytoskeleton with the plasma membrane. They are involved in
the formation of microvilli, cell-cell adhesion, maintenance of
cell shape, cell motility, and membrane trafficking (39, 40). In
addition, they are directly phosphorylated by ROCK, a direct
target of Rho (41). Therefore, we assessed the effects of LPA on
ERM proteins and found that LPA increased the phosphoryla-
tion of ERM proteins in SKOV3 cells. To detect phosphoryla-
tion of ERMproteins in Fig. 5,A andC, an immunoblot analysis
was performed, and two bands were detected at size of 75 kDa
and 80 kDa. The upper band represents ezrin phosphorylated at
Thr-567 and radixin phosphorylated at Thr-564, whereas the
lower band represents moesin phosphorylated at Thr-558 as
described previously (42). LPA-induced phosphorylation of
ERM proteins and cell migration were clearly suppressed in
FIGURE 3. LPA-activatedAMPK induces cellmigration throughCa2-dependent signaling.A and B, SKOV3 cellswere pretreatedwith 5MAMPK inhibitor
(Compound C), 10MMEK inhibitor (PD98059), 5M PLC inhibitor (U73122), 10CaMKK inhibitor (STO-609), or 0.1%DMSO for 30min and thenwith 2g/ml
pertussis toxin overnight before the addition of LPA. C and D, SKOV3 cells were transfected with control or PLC-3 siRNA for 48 h. E and F, SKOV3 cells were
transfected with control or CaMKK siRNA for 48 h. A, C, and E, cells were treated with 1 M LPA for 2 min under serum-free conditions. Cell lysates were
prepared and subjected to immunoblot analysis using specific antibodies against p-AMPK, AMPK1, PLC-3, and-actin. These results represent one of three
independent experiments. B, D, and F, the cells were used for a transwell migration assay after treatment with 1 M LPA for 4 h, as described under “Experi-
mental Procedures.” Each value is expressed as themean S.D. of three independent experiments, eachperformed in triplicate. *,p0.05 comparedwith LPA
alone. The efficiency of siRNA interference against CaMKKwas tested by RT-PCR (F).
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SKOV3 cells pretreated with Y27632, a ROCK inhibitor (Fig. 5,
A and B). Importantly, knockdown of AMPK1 by siRNA
transfection significantly reduced the LPA-induced phosphor-
ylation of ERM proteins (Fig. 5C). To confirm this effect, we
examined the subcellular localization of phosphorylated ERM
proteins in SKOV3 cells by an immunofluorescence analysis. In
agreement with Western blot analysis, treatment with LPA
leads to amarked increase in the intensity of phosphorylation of
ERM proteins. Moreover, phosphorylated ERM proteins were
exactly colocalized with F-actin structures localized in these
protrusions. However, knockdown of AMPK1 significantly
decreased the LPA-induced colocalization between phosphor-
ylated ERMproteins and F-actin (Fig. 5D). These results indicated
that AMPK triggers actin rearrangement for LPA-induced cell
migration by activation of ERM proteins through ROCK.
Knockdown of AMPK Decreases Peritoneal Dissemination
and LungMetastasis in Vivo—Ovarian cancermetastasizes pri-
marily on the peritoneum and rarely to distant sites. Subse-
quent peritoneal implants were characterized by the adhesion
and invasion of tumor cells into the peritoneum, leading to
miliary dissemination (43). Therefore, to analyze the in vivo
role of AMPK in peritoneal dissemination of ovarian cancer
cells, xenograftmodels were accomplished.We used lentivirus-
mediated shRNA to knock down the AMPK1 in SKOV3 cells.
Expression of AMPK1 was significantly decreased to 80–90%
in SKOV3 cells infected with AMPK1 shRNA compared with
control shRNA (data not shown). Female NOG mice were
injected intraperitoneally with control (SKOV3shControl) or
AMPK1 knockdown SKOV3 cells (SKOV3shAMPK1), and
tumors were allowed to grow for 8 weeks. After 8 weeks, the
tumor burden in the peritoneal surface was significantly higher
in the SKOV3shControl group than in the SKOV3shAMPK1 group
(Fig. 6A).Moreover, the representative size of peritoneal tumor
masses was 4–6mm in the SKOV3shControl group and 2–3mm
in the SKOV3shAMPK1 group (Fig. 6A). The number of perito-
neal tumor masses was reduced up to 50% (mean  S.D., p 
0.005, n 	 6 each) in the SKOV3shAMPK1 group when com-
pared with the SKOV3shControl group (Fig. 6C). Furthermore, a
significant decrease in lung metastases was observed in the
SKOV3shAMPK1 group (mean  S.D., p  0.05, n 	 6 each)
(Fig. 6, B and D). Taken together, these data indicated that
knockdown of AMPK decreases peritoneal dissemination and
lung metastasis in vivo.
DISCUSSION
The principal finding of this studywas that activation ofAMPK
by LPA significantly contributes to cell migration through
dynamic cytoskeletal rearrangements in ovarian cancer cells.
Several studies have suggested that cell migration is regu-
lated by the activation of AMPK in various cells types (44–47).
For example, activation of AMPK by adiponectin inhibits
lipopolysaccharide-induced adventitial fibroblast migration
(44), and insulin-like growth factor-1-induced vascular smooth
muscle cell migration is also suppressed by AMPK activation
(45). However, AMPK stimulates human umbilical vein endo-
thelium cell migration (46) and induces transendothelial lym-
phocyte migration by endothelial nitric-oxide synthase activa-
tion (47). In addition, hypertonicity- and A769662-induced
AMPK activation triggers actin cytoskeleton remodeling via
phosphorylation of ROCK downstream targets in Madin-
Darby Canine Kidney cells (48). Therefore, the role of AMPK in
cell migrationmay be dependent on which extracellular factors
are stimulated or occur in a cell type-specific manner. Because
the role of AMPK in cancer cell migration is especially unclear,
it is important to understand what factors trigger the activation
of AMPK and how this activation is regulated in cancer cells. In
this study, we found that the activation of AMPK by LPA was
required for cell migration through the activation of ERM pro-
teins in ovarian cancer cells.We thus considered the possibility
that AMPK is a positive regulator of LPA-induced cell migra-
tion in ovarian cancer cells.
AMPK has been shown to be activated by the upstream
kinase CaMKK (24, 25). The activation of AMPKbyCaMKK
is triggered by an increase in intracellular calcium concentra-
tion without detectable changes in the AMP-to-ATP ratio (24).
CaMKK induces cell migration through receptor-mediated
AMPK activation, such as vascular endothelial growth factor
receptor 2 (28). Therefore, AMPK activationmight be essential
for receptor-mediated Ca2 signaling in cell migration. LPA-
modulated Ca2 signaling has been shown previously to regu-
late cell migration (16). However, it is not fully understood how
LPA regulates the Ca2-mediated intracellular signaling path-
way in cell migration. In this study, we found that the inhibition
and knockdown of CaMKK significantly attenuated the LPA-
induced phosphorylation of AMPK and cell migration (Fig. 3, E
and F). In addition, treatment with 5-aminoimidazole-4-car-
boxamide ribonucleoside (AICAR), a known AMPK activator,
had no effect on ovarian cancer cell migration. Intracellular
Ca2 generation also did not have an effect upon AICAR treat-
ment (data not shown). Taken together, these results suggest
that the activation of AMPK might be important in coordinat-
FIGURE 4. LPA induces activation of RhoA through AMPK. A, SKOV3 cells
were stimulated for the indicated times with 10 M LPA under serum-free
conditions. B, SKOV3 cells were transfected with control and AMPK1 siRNA
for 48 h and then stimulated with 10 M LPA for 2 min under serum-free
conditions. Activated RhoA or Rac1 was isolated using GST-Rhotekin or GST-
Pak bound to glutathione-Sepharose beads. RhoA or Rac1 bound to the
beadswasdetectedby immunoblot analysis using specific antibodies against
RhoA or Rac1. Total cell lysates were prepared and subjected to immunoblot
analysis using specific antibodies against p-AMPK, AMPK1, RhoA, Rac1, and
-actin. AMPK1, RhoA, and Rac1 were used as experimental controls, and
-actin was used as the loading control. These results represent one of three
independent experiments.
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ing other LPA-induced pathways, including Ca2 signaling in
LPA-induced cell migration.
Multiple intracellular pathways are well documented in
LPA-induced migration of ovarian cancer cells. The Gi-Ras-
MEKK1 signaling pathway mediates LPA-stimulated ovarian
cancer cell migration by facilitating focal adhesion kinase redis-
tribution to focal contacts (14). Also, LPA-induced Rac activa-
tion requires phosphoinositide 3-kinase activity through LPA1
and thereby promotes cell spreading, lamellipodium formation,
and cell migration (15). In this study, we found that the knock-
down of AMPK1 significantly attenuated LPA-induced RhoA
activation but not Rac activation (Fig. 4B). Because LPA-in-
duced AMPK phosphorylation was associated with LPA2 acti-
vation, LPA-induced Rac activation through LPA1 might have
no effect on ovarian cancer cell migration. In addition, the Gi/o
inhibitor pertussis toxin significantly reduced LPA-induced
phosphorylation of AMPK and cell migration (Fig. 3, A and B).
We thus considered the possibility that AMPK activation by
LPA induces ovarian cancer cell migration through the Gi-Ras-
MEKK1 signaling pathway.
The migratory response to LPA was associated with LPA2-
mediated action in ovarian cancer cells (Fig. 1E). It has been
reported recently that overexpression of LPA2 in ovarian can-
cer cells was more efficient at increasing in vitro motility and
invasion and in vivo tumor growth, particularly metastasis to
distant organs including skeletal muscle, cervical lymph nodes,
and the heart (49). In this study, we have shown that the expres-
sion levels of LPA2 andLPA3 aberrantly up-regulated in ovarian
FIGURE5.AMPKactivatesERMproteins inLPA-inducedcellmigration.AandB, SKOV3cellswerepretreatedwith10MY27632, aROCK inhibitor, for 30min
before the addition of LPA. C and D, SKOV3 cells were transfected with control or AMPK1 siRNA for 48 h. A and C, the cells were stimulated with 1M LPA for
2 min under serum-free conditions. Cell lysates were prepared and subjected to immunoblot analysis using specific antibodies against p-ERM, p-AMPK, ERM,
AMPK1, and-actin. These results represent oneof three independent experiments.B, the cellswereused for a transwellmigration assay after treatmentwith
1MLPA for 4h, asdescribedunder “Experimental Procedures.” Eachvalue is expressedas themeanS.D. of three independent experiments, eachperformed
in triplicate. *, p 0.05 compared with LPA alone. D, transfected cells were plated on collagen type I-coated dishes and stimulated with 1 M LPA for 5 min
under serum-free conditions. Cells were labeled with p-ERM antibody (green) or rhodamine-labeled phalloidin (red). Cells were analyzed by confocal micros-
copy. The arrows indicate membrane protrusions.
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cancer cells compared with normal ovarian surface epithelial
cells (Fig. 1C). Moreover, knockdown of LPA2 significantly
attenuated LPA-induced AMPK phosphorylation but not
knockdown of LPA3 (Fig. 1D). In addition, peritoneal dissemi-
nation and lung metastases were decreased by knockdown of
AMPK in vivo using xenografts in NOG mice (Fig. 6). Collec-
tively, our results indicated that the activation ofAMPKby LPA
might play a crucial role in LPA2-mediated tumor progression,
particularly metastasis.
Cell migration begins with an initial protrusion or extension of
the plasmamembrane at the leading edge of the cell. The protru-
sion is driven by polymerization of a network of cytoskeletal actin
filaments and is stabilized through the formation of an adhesive
complex (50). To explain the underlyingmolecularmechanism of
AMPK-mediated cytoskeleton rearrangements in LPA-induced
cell migration, we analyzed the activation of small GTPases that
induced particular surface protrusions generated by actin-remod-
eling reactions (51, 52). Interestingly, our data revealed that LPA-
activated AMPK enhances RhoA activation (Fig. 4). Our novel
identification of a RhoA-ROCK-ERM axis through activation of
AMPKbyLPAledus tohypothesize thatRhoAmightplaya role in
the AMPK-mediated actin cytoskeleton remodeling in SKOV3
cells. However, the regulatory mechanism of AMPK-activated
small GTPases is unclear. It has been reported that phosphoryla-
tion is the regulatorymechanism of RhoGTPase activation and is
independentofGDP-GTPcycling (53). cAMP-andcGMP-depen-
dent kinases (PKA and PKG, respectively) have been shown to
phosphorylate RhoA on Ser-188 (54, 55). Additionally, LPA
induces threonine phosphorylation of the Rac1-specific nucleo-
tide exchange factor Tiam1 through protein kinase C (56). It is
therefore possible that AMPK increases the activation of small
GTPases or regulatory proteins of smallGTPases, such as guanine
FIGURE 6. Knockdown of AMPK decreases peritoneal dissemination and lung metastasis in vivo. NOG mice (n 	 6 per group) were injected with
SKOV3shControl or SKOV3shAMPK1 cells and euthanized 8 weeks after injection. A, representative views of the metastasis in the peritoneal cavity of mice. The
arrows indicate peritoneal tumormasses. B, hematoxylin and eosin stainingof lungs fromNOGmice injectedwith SKOV3shControl or SKOV3shAMPK1. Scale bar	
50m. C, the number of peritoneal tumormasses was counted.D, the number of lungmetastaticmasses (size;
 1mm)was counted. Each value is expressed
as the mean S.D. of two independent experiments. *, p 0.05, **, p 0.005, difference with SKOV3shControl.
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nucleotide exchange factor, GDP dissociation inhibitor, and
GTPase activating protein, by phosphorylation.
In conclusion, AMPK is an important regulatory factor for
ovarian cancer cell migration through LPA2-mediated cyto-
skeleton reorganization and tumor metastasis in vivo. Thus,
AMPK may be a key therapeutic target for the control of ovar-
ian cancer progression.
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